{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:56Z","timestamp":1792644116247,"version":"4.5.0"},"reference-count":41,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0327","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T08:23:02Z","timestamp":1525335782000},"source":"Crossref","is-referenced-by-count":35,"title":["The Differential Diagnosis and Treatment of Thrombotic Microangiopathies"],"prefix":"10.3238","author":[{"given":"Martin","family":"Bommer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"W\u00f6lfle-Guter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Bohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kuchenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"10.3238\/arztebl.2018.0327_ref1","doi-asserted-by":"crossref","unstructured":"George JN, Nester CM: Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 1847\u20138","DOI":"10.1056\/NEJMc1410951"},{"key":"10.3238\/arztebl.2018.0327_ref2","doi-asserted-by":"crossref","unstructured":"Shatzel JJ, Taylor JA: Syndromes of thrombotic microangiopathy. Med Clin North Am 2017; 101: 395\u2013415","DOI":"10.1016\/j.mcna.2016.09.010"},{"key":"10.3238\/arztebl.2018.0327_ref3","doi-asserted-by":"crossref","unstructured":"Rock GA, Shumak KH, Buskard NA, et al.: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393\u20137","DOI":"10.1056\/NEJM199108083250604"},{"key":"10.3238\/arztebl.2018.0327_ref4","doi-asserted-by":"crossref","unstructured":"Amarosi EL, Ultmann JE: Thrombotic thrombozytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139\u201360","DOI":"10.1097\/00005792-196603000-00003"},{"key":"10.3238\/arztebl.2018.0327_ref5","doi-asserted-by":"crossref","unstructured":"Scully M, Hunt BJ, Benjamin S, et al.: Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323\u201335","DOI":"10.1111\/j.1365-2141.2012.09167.x"},{"key":"10.3238\/arztebl.2018.0327_ref6","doi-asserted-by":"crossref","unstructured":"Moschcowitz E: An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease. Am J Med 1952; 13: 567\u20139","DOI":"10.1016\/0002-9343(52)90022-3"},{"key":"10.3238\/arztebl.2018.0327_ref7","doi-asserted-by":"crossref","unstructured":"Brocklebank V, Wood KM, Kavanagh D: Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018; 13: 300\u201317","DOI":"10.2215\/CJN.00620117"},{"key":"10.3238\/arztebl.2018.0327_ref8","doi-asserted-by":"crossref","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN: Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 2017; 1: 590\u2013600","DOI":"10.1182\/bloodadvances.2017005124"},{"key":"10.3238\/arztebl.2018.0327_ref9","doi-asserted-by":"crossref","unstructured":"Bettoni G, Palla R, Valsecchi C, et al.: ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 1556\u201365","DOI":"10.1111\/j.1538-7836.2012.04808.x"},{"key":"10.3238\/arztebl.2018.0327_ref10","doi-asserted-by":"crossref","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN: Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood 2016; 128: 2175\u20138","DOI":"10.1182\/blood-2016-06-724161"},{"key":"10.3238\/arztebl.2018.0327_ref11","doi-asserted-by":"crossref","unstructured":"Camilleri RS, Scully M, Thomas M, et al.: A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012; 10: 1792\u2013801","DOI":"10.1111\/j.1538-7836.2012.04852.x"},{"key":"10.3238\/arztebl.2018.0327_ref12","doi-asserted-by":"crossref","unstructured":"Schwartz J, Padmanabhan A, Aqui N, et al.: Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue. J Clin Apher 2016; 31: 149\u201362","DOI":"10.1002\/jca.21470"},{"key":"10.3238\/arztebl.2018.0327_ref13","doi-asserted-by":"crossref","unstructured":"George JN: How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060\u20139","DOI":"10.1182\/blood-2010-07-271445"},{"key":"10.3238\/arztebl.2018.0327_ref14","doi-asserted-by":"crossref","unstructured":"Scully M, McDonald V, Cavenagh J, et al.: A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746\u201353","DOI":"10.1182\/blood-2011-03-341131"},{"key":"10.3238\/arztebl.2018.0327_ref15","doi-asserted-by":"crossref","unstructured":"Matsumoto M, Fujimura Y, Wada H, et al.: Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol 2017; 106: 3\u201315","DOI":"10.1007\/s12185-017-2264-7"},{"key":"10.3238\/arztebl.2018.0327_ref16","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C: Haemolytic uraemic syndrome. The Lancet 2017; 390: 681\u201396","DOI":"10.1016\/S0140-6736(17)30062-4"},{"key":"10.3238\/arztebl.2018.0327_ref17","unstructured":"Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R: [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr 1955; 85: 905\u20139"},{"key":"10.3238\/arztebl.2018.0327_ref18","doi-asserted-by":"crossref","unstructured":"Rahaman MM, Greenough WB, 3rd: Shigellosis and haemolytic uraemic syndrome. Lancet 1978; 1: 1051","DOI":"10.1016\/S0140-6736(78)90784-5"},{"key":"10.3238\/arztebl.2018.0327_ref19","doi-asserted-by":"crossref","unstructured":"Loirat C, Fakhouri F, Ariceta G, et al.: An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31: 15\u201339","DOI":"10.1007\/s00467-015-3076-8"},{"key":"10.3238\/arztebl.2018.0327_ref20","doi-asserted-by":"crossref","unstructured":"Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS: Long-term outcomes of shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013; 28: 2097\u2013105","DOI":"10.1007\/s00467-012-2383-6"},{"key":"10.3238\/arztebl.2018.0327_ref21","doi-asserted-by":"crossref","unstructured":"Gruppo RA, Rother RP: Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544\u20136","DOI":"10.1056\/NEJMc0809959"},{"key":"10.3238\/arztebl.2018.0327_ref22","doi-asserted-by":"crossref","unstructured":"Legendre CM, Licht C, Muus P, et al.: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169\u201381","DOI":"10.1056\/NEJMoa1208981"},{"key":"10.3238\/arztebl.2018.0327_ref23","doi-asserted-by":"crossref","unstructured":"Page EE, Little DJ, Vesely SK, George JN: Quinine-induced thrombotic microangiopathy: a report of 19 patients. Am J Kidney Dis 2017; 70: 686\u201395","DOI":"10.1053\/j.ajkd.2017.05.023"},{"key":"10.3238\/arztebl.2018.0327_ref24","doi-asserted-by":"crossref","unstructured":"Bennett CL, Jacob S, Dunn BL, et al.: Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). Br J Haematol 2013; 161: 896\u20138","DOI":"10.1111\/bjh.12303"},{"key":"10.3238\/arztebl.2018.0327_ref25","doi-asserted-by":"crossref","unstructured":"Masias C, Vasu S, Cataland SR: None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood 2017; 129: 2857\u201363","DOI":"10.1182\/blood-2016-11-743104"},{"key":"10.3238\/arztebl.2018.0327_ref26","doi-asserted-by":"crossref","unstructured":"Bohl SR, Kuchenbauer F, von Harsdorf S, et al.: Thrombotic microangiopathy after allogeneic stem cell transplantation\u2014a comparison of eculizumab therapy and conventional therapy. Biol Blood Marrow Transplant 2017; 23: 2172\u20137","DOI":"10.1016\/j.bbmt.2017.08.019"},{"key":"10.3238\/arztebl.2018.0327_ref27","doi-asserted-by":"crossref","unstructured":"Bergmann F, Rath W: The differential diagnosis of thrombocytopenia in pregnancy. Dtsch Arztebl Int 2015; 112: 795\u2013802","DOI":"10.3238\/arztebl.2015.0795"},{"key":"10.3238\/arztebl.2018.0327_ref28","doi-asserted-by":"crossref","unstructured":"Scully M: Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost 2016; 42: 774\u20139","DOI":"10.1055\/s-0036-1587683"},{"key":"10.3238\/arztebl.2018.0327_ref29","doi-asserted-by":"crossref","unstructured":"Lechner K, Obermeier HL: Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 2012; 91: 195\u2013205","DOI":"10.1097\/MD.0b013e3182603598"},{"key":"10.3238\/arztebl.2018.0327_ref30","doi-asserted-by":"crossref","unstructured":"Erkan D, Salmon JE: The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk J Haematol 2016; 33: 1\u20137","DOI":"10.4274\/tjh.2015.0197"},{"key":"10.3238\/arztebl.2018.0327_ref31","doi-asserted-by":"crossref","unstructured":"Perez-Rodriguez A, Loures E, Rodriguez-Trillo A, et al.: Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review. Thromb Res 2014; 134: 1171\u20135","DOI":"10.1016\/j.thromres.2014.09.004"},{"key":"10.3238\/arztebl.2018.0327_ref32","doi-asserted-by":"crossref","unstructured":"Crovetto F, Borsa N, Acaia B, et al.: The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med 2012; 25: 2322\u20135","DOI":"10.3109\/14767058.2012.694923"},{"key":"10.3238\/arztebl.2018.0327_ref33","doi-asserted-by":"crossref","unstructured":"Rodriguez-Pinto I, Moitinho M, Santacreu I, et al.: Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 2016; 15: 1120\u20134","DOI":"10.1016\/j.autrev.2016.09.010"},{"key":"10.3238\/arztebl.2018.0327_ref34","doi-asserted-by":"crossref","unstructured":"Barber C, Herzenberg A, Aghdassi E, et al.: Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 2012; 7: 757\u201364","DOI":"10.2215\/CJN.02870311"},{"key":"10.3238\/arztebl.2018.0327_ref35","doi-asserted-by":"crossref","unstructured":"Pisoni R, Ruggenenti P, Remuzzi G: Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf 2001; 24: 491\u2013501","DOI":"10.2165\/00002018-200124070-00002"},{"key":"10.3238\/arztebl.2018.0327_ref36","doi-asserted-by":"crossref","unstructured":"Grange S, Coppo P, Centre de r\u00e9f\u00e9rence des microangiopathies thrombotiques (CNR-MAT): Thrombotic microangiopathies and antineoplastic agents. Nephrol Ther 2017; 13 Suppl 1: 109\u201313","DOI":"10.1016\/j.nephro.2017.01.016"},{"key":"10.3238\/arztebl.2018.0327_ref37","doi-asserted-by":"crossref","unstructured":"Jodele S, Zhang K, Zou F, et al.: The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016; 127: 989\u201396","DOI":"10.1182\/blood-2015-08-663435"},{"key":"10.3238\/arztebl.2018.0327_ref38","doi-asserted-by":"crossref","unstructured":"Becker S, Fusco G, Fusco J, et al.: HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39 Suppl 5: 267\u201375","DOI":"10.1086\/422363"},{"key":"10.3238\/arztebl.2018.0327_ref39","doi-asserted-by":"crossref","unstructured":"Sheerin NS, Kavanagh D, Goodship TH, Johnson S: A national specialized service in England for atypical haemolytic uraemic syndrome\u2014the first year\u2018s experience. QJM 2016; 109: 27\u201333","DOI":"10.1093\/qjmed\/hcv082"},{"key":"10.3238\/arztebl.2018.0327_ref40","doi-asserted-by":"crossref","unstructured":"Prestidge C, Wong W: Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children. J Paediatr Child Health 2009; 45: 731\u20135","DOI":"10.1111\/j.1440-1754.2009.01603.x"},{"key":"10.3238\/arztebl.2018.0327_ref41","doi-asserted-by":"crossref","unstructured":"Bell WR, Braine HG, Ness PM, Kickler TS: Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398\u2013403","DOI":"10.1056\/NEJM199108083250605"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:39:10Z","timestamp":1638797950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":41,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0327","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]}}}